The clinical relevance of ERβ expression in breast cancer remains controversial largely due to challenges associated with ERβ splice variants and post-translational modifications, as well as the lack of a clinically standardized ERβ antibody [19,30,31]. Here, ESR2 is linked to breast carcinoma.